Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801

Entrada Therapeutics, Inc.

Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.
Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.
On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.
Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.
Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026.

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.